ClinicalTrials.gg
RecruitingNCT03104491Updated Sep 10, 2026

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

A Phase 1/2 interventional study of Inotuzumab Ozogamicin in Acute Lymphocytic Leukemia, sponsored by Leland Metheny. Recruiting at 7 sites in United States. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Leland Metheny · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2017; still recruiting 9 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
16 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies testing Inotuzumab Ozogamicin in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 8 open to participants now, 11 under way, none of them phase 3. Inotuzumab Ozogamicin · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Planned enrollment
11th of 20
44 · median 47
Started
2017
with 2 others
Phase 1/2
Only one
of the 20
Primary completion
2026-11
later than 4 of 10 live
Registered
6th of 20
by date
Lead sponsor
1 of 20
Leland Metheny

Among the 20 studies testing Inotuzumab Ozogamicin in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 11th largest by planned enrollment, is one of 3 that started in 2017, is the only one in phase 1/2, reaches primary completion later than 4 of the 10 other live ones, and was the 6th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

8 of the 20 studies testing Inotuzumab Ozogamicin in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About Inotuzumab Ozogamicin

Inotuzumab Ozogamicin: first FDA approval 2017 (BESPONSA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 16 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing Inotuzumab Ozogamicin in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects.

The Phase II portion of this study is to see what side effects are seen with medication after transplant.

Inotuzumab ozogamicin is a combination of an antibody and chemotherapy which has been shown to have significant activity against relapsed/refractory acute lymphocytic leukemia (ALL).

Inotuzumab ozogamicin is considered experimental in this study.

Read the detailed description

Study Design This is a Phase I/II study of inotuzumab ozogamicin for the treatment of patients who underwent allogeneic transplantation for ALL and have a high risk of relapse. The Phase I portion of this study will be a 3+3 dose escalation trial. This is followed by a phase 2 cohort at the recommended Phase 2 dose (RP2D). Participants will receive study treatment up to 4 cycles until relapse of disease, unacceptable toxicity, or death, whichever occurs first

Phase I: Inotuzumab Ozogamicin Dosing Escalation Subjects will be assessed for safety and tolerability (including adverse events, serious adverse events, and clinical/laboratory assessments) using a continuous monitoring approach.

Phase II: Inotuzumab Ozogamicin Subjects will be assessed for safety and tolerability (including adverse events, serious adverse events, and clinical/laboratory assessments) using a continuous monitoring approach. In order to be included in the safety profile endpoint review, subjects must have received at least of 1 cycle of treatment.

Primary Objective

Phase I: To define a post hematopoietic stem cell transplantation maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of inotuzumab ozogamicin.

Phase II: To assess the efficacy of inotuzumab ozogamicin as measured by diseasefree survival (DFS) at one year.

Secondary Objective(s)

Phase I:

  • To evaluate disease-free survival (DFS), nonrelapse mortality (NRM), relapse, relapse-related mortality and overall survival (OS) at 1 year.
  • To determine safety profile of inotuzumab ozogamicin after transplant including the incidence of myeloid toxicity and secondary graft failure and the rate of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS).
  • To determine if inotuzumab ozogamicin at these doses is effective at eradicating minimal residual disease in this cohort of participants

Phase II:

  • To assess additional evidence of efficacy and safety as measured by non-relapse mortality (NRM), relapse, relapse-related mortality and overall survival (OS) at 1 year.
  • To determine if inotuzumab ozogamicin at these doses is effective at eradicating MRD.
  • To confirm the safety profile of inotuzumab ozogamicin therapy after transplant including myeloid toxicity, secondary graft failure, and the rate of VOD/SOS.
  • To evaluate the pharmacokinetics of inotuzumab ozogamicin post allogeneic transplant
03

Conditions studied

  • Acute Lymphocytic Leukemia

Keywords

  • allogeneic hematopoietic stem cell transplantation
  • donor chimerism
04

Who can participate

Ages eligible
16 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Phase 1 Inclusion Criteria

  • Diagnosis of CD22-positive Acute Lymphoblastic Leukemia
  • Patients who underwent an hematopoietic stem cell transplantation from any donor source for acute lymphocytic leukemia
  • Patients who are between T+40 and T+100 after allogeneic transplantation. Patients must receive their first dose of inotuzumab at or before T+100.
  • Patients who have/are either:

    • Transplanted in hematologic first complete remission with evidence of minimal residual disease within 45 days of allogeneic transplantation

      ---Pre- or Post-Transplant Minimal Residual Disease defined by:

      ----Any detectable ALL (by flow cytometry, cytogenetics, or PCR techniques) as per clinical indication.

    • In second or third complete remission at the time of allogeneic transplantation
    • Treated with reduced intensity regimens or non-myeloablative conditioning regimens
    • Lymphoid blast crisis of CML
    • Are to at least 1
    • Philadelphia-like ALL
  • Patients who have evidence of donor chimerism after allogeneic transplantation.
  • Performance status \< 2
  • Participants must have > 1,000/µL for 3 days and transfusion independence as defined as a platelet count > 50,000/µL for 7 days.
  • Able to adhere to the study visit schedule and other protocol requirements.
  • Participants must have the ability to understand and the willingness to sign a written document.

Phase 2 Inclusion Criteria

  • Diagnosis of CD22-positive Acute Lymphoblastic Leukemia
  • Patients who underwent an allogeneic hematopoietic stem cell transplantation from any donor source for acute lymphocytic leukemia
  • Patients who are between T+40 and T+100 after allogeneic transplantation
  • Patients who have/are either:

    • Transplanted in hematologic first complete remission with evidence of minimal residual disease within 45 days of allogeneic transplantation

      ---Post-Transplant Minimal Residual Disease defined by:

      ----Any detectable ALL (by flow cytometry, cytogenetics, or PCR techniques) as per clinical indication.

    • In second or third complete remission at the time of allogeneic transplantation
    • Treated with reduced intensity regimens as defined per institutional standard of practice
    • Lymphoid blast crisis of CML
    • Are relapsed or refractory to at least 1 line of chemotherapy
    • Philadelphia-like ALL
  • Patients who have > 80% donor chimerism after allogeneic transplantation.
  • Philadelphia chromosome positive ALL must have failed at least 1 TKI
  • ECOG Performance status \< 1
  • pre-transplant evaluation, see 10.1.1
  • Participants must have ANC > 1,000/µL for 3 days and platelet transfusion independence as defined as a platelet count > 50,000/µL for 7 days.
  • Able to adhere to the study visit schedule and other protocol requirements.
  • Participants must have the ability to understand and the willingness to sign a written informed consent document.

Phase 1 and 2 Exclusion Criteria:

  • Patients with clinical evidence of disease progression prior to enrollment
  • Persistent prior treatment toxicities Grade 2 and above according to Version 4.03 (with the exception for alopecia, neuropathy, etc.)
  • Patients with inadequate organ function as defined by:

    • \< 30ml/min
    • > 2X institutional
    • (SGOT) > 2X institutional upper limit of normal
    • ALT (SGPT) > 2X institutional upper limit of normal
  • grade III or IV (for patients with a prior allogeneic transplant).
  • Active acute or chronic GVHD of the liver (for patients with a prior allogeneic transplant)
  • History of VOD
  • Use of concomitant TKI or sirolimus
  • Second active , other than non-melanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast)
  • Patients with uncontrolled inter-current illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant or breastfeeding women are excluded from this study because inotuzumab ozogamicin may be associated with the potential for teratogenic or abortifacient effects. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with inotuzumab ozogamicin, breastfeeding should be discontinued if the mother is treated with inotuzumab ozogamicin. These potential risks may also apply to other agents used in this study.
  • Evidence of myelodysplasia or cytogenetic abnormality indicative of myelodysplasia on any bone marrow prior to initiation of therapy Serologic status reflecting active or C infection. Patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive patients will be excluded.)
  • Serologic status reflecting active hepatitis B or C infection. Patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive patients will be excluded.)
  • Participation in any other drug study or had exposure to any other investigational agent, device, or procedure, within 21 days (or 5 half-lives, whichever is greater)
  • Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
  • Known allergies, , or intolerance to any of the study medications, , or similar compounds
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Inotuzumab Ozogamicin

    Phase I: A maximum of 4 cycles will be allowed and doses will be adjusted in 0.1mg/m2 increments using a dose escalation scale depending on tolerability. Total range of dose levels for participants is 0.1-0.6mg/m\^2. Phase II: Participants will be enrolled until all Phase I participants have been followed and assessed for toxicity for at least 4 weeks after the fourth treatment dose of inotuzumab ozogamicin or 4 weeks after the participant goes off treatment, whichever comes first. Doses to be administered will be determined in the phase I portion of the study. The recommended phase 2 dose is 0.3mg/m2. Repeat cycles every 28 days for up to 4 cycles

    Drug: Inotuzumab Ozogamicin

Interventions

  • Inotuzumab ozogamicin, IV, 28 day cycles Phase 1 dosages: Dose Level -2 (0.1 mg/m\^2) Dose Level -1 (0.2 mg/m\^2) Dose Level 0 (0.3 mg/m\^2) Dose Level 1 (0.4 mg/m\^2) Dose Level 2 (0.5 mg/m\^2) Dose Level 3 (0.6 mg/m\^2)

06

What researchers measure

Primary outcomes

  1. Phase I MTD

    Defined post hematopoietic stem cell transplantation MTD

    Time frame: Up to 112 days (16 weeks)

  2. Phase I DLTs

    Frequency of DLTs during the first two cycles in ALL-participants

    Time frame: Up to 112 days (16 weeks)

  3. Phase II Median DFS

    Efficacy as measured by phase II DFS at one year, estimated using Kaplan-Meier, reported as median and 2-sided 80% and 95% Confidence Interval (CI) DFS is defined as "Time from date of first dose to the date of disease progression (ie,objective progression, relapse from CR/CRi), or death due to any cause, whichever occurs first (including post-study treatment follow-up disease assessments)". Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10 In Phase II, the null hypothesis of H0: DFS at 1-year ≤ 55% versus the alternative hypothesis of Ha: DFS at 1-year ≥ 75% using 1-sided alpha of 10% will be tested

    Time frame: At 3 months after initial treatment

  4. Phase II Median DFS

    Efficacy as measured by phase II DFS at one year, estimated using Kaplan-Meier, reported as median and 2-sided 80% and 95% Confidence Interval (CI) DFS is defined as "Time from date of first dose to the date of disease progression (ie,objective progression, relapse from CR/CRi), or death due to any cause, whichever occurs first (including post-study treatment follow-up disease assessments)". Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10 In Phase II, the null hypothesis of H0: DFS at 1-year ≤ 55% versus the alternative hypothesis of Ha: DFS at 1-year ≥ 75% using 1-sided alpha of 10% will be tested

    Time frame: At 6 months after initial treatment

  5. Phase II Median DFS

    Efficacy as measured by phase II DFS at one year, estimated using Kaplan-Meier, reported as median and 2-sided 80% and 95% Confidence Interval (CI) DFS is defined as "Time from date of first dose to the date of disease progression (ie,objective progression, relapse from CR/CRi), or death due to any cause, whichever occurs first (including post-study treatment follow-up disease assessments)". Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10 In Phase II, the null hypothesis of H0: DFS at 1-year ≤ 55% versus the alternative hypothesis of Ha: DFS at 1-year ≥ 75% using 1-sided alpha of 10% will be tested

    Time frame: At 9 months after initial treatment

  6. Phase II Median DFS

    Efficacy as measured by phase II DFS at one year, estimated using Kaplan-Meier, reported as median and 2-sided 80% and 95% Confidence Interval (CI) DFS is defined as "Time from date of first dose to the date of disease progression (ie,objective progression, relapse from CR/CRi), or death due to any cause, whichever occurs first (including post-study treatment follow-up disease assessments)". Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10 In Phase II, the null hypothesis of H0: DFS at 1-year ≤ 55% versus the alternative hypothesis of Ha: DFS at 1-year ≥ 75% using 1-sided alpha of 10% will be tested

    Time frame: At 1 year after initial treatment

  7. Phase II Median DFS

    Efficacy as measured by phase II DFS at one year, estimated using Kaplan-Meier, reported as median and 2-sided 80% and 95% Confidence Interval (CI) DFS is defined as "Time from date of first dose to the date of disease progression (ie,objective progression, relapse from CR/CRi), or death due to any cause, whichever occurs first (including post-study treatment follow-up disease assessments)". Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10 In Phase II, the null hypothesis of H0: DFS at 1-year ≤ 55% versus the alternative hypothesis of Ha: DFS at 1-year ≥ 75% using 1-sided alpha of 10% will be tested

    Time frame: Post first dose of inotuzumab ozogamicin

Secondary outcomes

  1. Phase I Median DFS

    Efficacy as measured by phase I DFS at one year. Estimated using Kaplan-Meier, reported as median and 2-sided 80% and 95% Confidence Interval (CI) DFS is defined as "Time from date of first dose to the date of disease progression (ie,objective progression, relapse from CR/CRi), or death due to any cause, whichever occurs first (including post-study treatment follow-up disease assessments)" Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10

    Time frame: At 3 months after initial treatment

  2. Phase I Median DFS

    Efficacy as measured by phase I DFS at one year. Estimated using Kaplan-Meier, reported as median and 2-sided 80% and 95% Confidence Interval (CI) DFS is defined as "Time from date of first dose to the date of disease progression (ie,objective progression, relapse from CR/CRi), or death due to any cause, whichever occurs first (including post-study treatment follow-up disease assessments)" Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10

    Time frame: At 6 months after initial treatment

  3. Phase I Median DFS

    Efficacy as measured by phase I DFS at one year. Estimated using Kaplan-Meier, reported as median and 2-sided 80% and 95% Confidence Interval (CI) DFS is defined as "Time from date of first dose to the date of disease progression (ie,objective progression, relapse from CR/CRi), or death due to any cause, whichever occurs first (including post-study treatment follow-up disease assessments)" Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10

    Time frame: At 9 months after initial treatment

  4. Phase I Median DFS

    Efficacy as measured by phase I DFS at one year. Estimated using Kaplan-Meier, reported as median and 2-sided 80% and 95% Confidence Interval (CI) DFS is defined as "Time from date of first dose to the date of disease progression (ie,objective progression, relapse from CR/CRi), or death due to any cause, whichever occurs first (including post-study treatment follow-up disease assessments)" Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10

    Time frame: At 1 year after initial treatment

  5. Phase I Median DFS

    Efficacy as measured by phase I DFS at one year. Estimated using Kaplan-Meier, reported as median and 2-sided 80% and 95% Confidence Interval (CI) DFS is defined as "Time from date of first dose to the date of disease progression (ie,objective progression, relapse from CR/CRi), or death due to any cause, whichever occurs first (including post-study treatment follow-up disease assessments)" Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10

    Time frame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days

  6. Phase I NRM

    Phase I NRM, defined as time from date of first dose to death due to any cause without prior relapse. Criteria used: For ALL, evidence of disease in the blood or bone marrow (flow cytometry or PCR). Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI

    Time frame: At 3 months after initial treatment

  7. Phase I NRM

    Phase I NRM, defined as time from date of first dose to death due to any cause without prior relapse. Criteria used: For ALL, evidence of disease in the blood or bone marrow (flow cytometry or PCR). Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI

    Time frame: At 6 months after initial treatment

  8. Phase I NRM

    Phase I NRM, defined as time from date of first dose to death due to any cause without prior relapse. Criteria used: For ALL, evidence of disease in the blood or bone marrow (flow cytometry or PCR). Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI

    Time frame: At 9 months after initial treatment

  9. Phase I NRM

    Phase I NRM, defined as time from date of first dose to death due to any cause without prior relapse. Criteria used: For ALL, evidence of disease in the blood or bone marrow (flow cytometry or PCR). Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI

    Time frame: At 1 year after initial treatment

  10. Phase I NRM

    Phase I NRM , defined as time from date of first dose to death due to any cause without prior relapse. Criteria used: For ALL, evidence of disease in the blood or bone marrow (flow cytometry or PCR). Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI

    Time frame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days

  11. Phase I Relapse

    Phase I relapse rate, defined as time from date of first dose to the date of first relapse. Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI

    Time frame: At 3 months after initial treatment

  12. Phase I Relapse

    Phase I relapse rate, defined as time from date of first dose to the date of first relapse. Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI

    Time frame: At 6 months after initial treatment

  13. Phase I Relapse

    Phase I relapse rate, defined as time from date of first dose to the date of first relapse. Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI

    Time frame: At 9 months after initial treatment

  14. Phase I Relapse

    Phase I relapse rate, defined as time from date of first dose to the date of first relapse. Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI

    Time frame: At 1 year after initial treatment

  15. Phase I Relapse

    Phase I relapse rate, defined as time from date of first dose to the date of first relapse. Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI

    Time frame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days

  16. Phase I Relapse-related mortality

    Phase I Relapse-related mortality, defined time from date of first dose to death due to any cause with prior relapse Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI

    Time frame: At 3 months after initial treatment

  17. Phase I Relapse-related mortality

    Phase I Relapse-related mortality, defined time from date of first dose to death due to any cause with prior relapse Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI

    Time frame: At 6 months after initial treatment

  18. Phase I Relapse-related mortality

    Phase I Relapse-related mortality, defined time from date of first dose to death due to any cause with prior relapse Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI

    Time frame: At 9 months after initial treatment

  19. Phase I Relapse-related mortality

    Phase I Relapse-related mortality, defined time from date of first dose to death due to any cause with prior relapse Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI

    Time frame: At 1 year after initial treatment

  20. Phase I Relapse-related mortality

    Phase I Relapse-related mortality, defined time from date of first dose to death due to any cause with prior relapse Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI

    Time frame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days

  21. Phase I Median OS

    Phase I OS, defined from time from date of first dose to death due to any cause, estimated using Kaplan-Meier, reported as median and 95% CI Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10

    Time frame: At 3 months after initial treatment

  22. Phase I Median OS

    Phase I OS, defined from time from date of first dose to death due to any cause, estimated using Kaplan-Meier, reported as median and 95% CI Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10

    Time frame: At 6 months after initial treatment

  23. Phase I Median OS

    Phase I OS, defined from time from date of first dose to death due to any cause, estimated using Kaplan-Meier, reported as median and 95% CI Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10

    Time frame: At 9 months after initial treatment

  24. Phase I Median OS

    Phase I OS, defined from time from date of first dose to death due to any cause, estimated using Kaplan-Meier, reported as median and 95% CI Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10

    Time frame: At 1 year after initial treatment

  25. Phase I Median OS

    Phase I OS, defined from time from date of first dose to death due to any cause, estimated using Kaplan-Meier, reported as median and 95% CI Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10

    Time frame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days

  26. Phase I Incidence of myeloid toxicity

    Number of patients who develop myeloid toxicity while on study, defined as grade of anemia, neutropenia and thrombocytopenia CTCAE 4

    Time frame: At 1 year

  27. Phase I Incidence of secondary graft failure

    Number of patients who develop secondary graft failure while on study, defined as: Either cytopenias after initial engraftment (ANC \<500/µL), with (a) donor chimerism of less than 5% or (b) falling donor chimerism with intervention such as second transplant or donor lymphocyte infusion (DLI) or (c) patient death due to cytopenias, and fall in donor chimerism, even if chimerism was \>5%. Exclusion criteria for diagnosis of GF were (a) disease relapse (b) graft versus host disease or (c) other causes of cytopenias such as, viral infections, or drug induced

    Time frame: At 1 year

  28. Phase I incidence of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)

    Safety profile of intervention as measured by incidence of VOD/SOS disease in the phase I portion of the study, defined as the occurrence of 2 of the following 3 clinical criteria: * Total serum bilirubin level \>34 μmol/L (\>2.0 mg/dL). * An increase in liver size from baseline or development of right upper quadrant pain of liver origin. * Sudden weight gain \>2.5% during any 72-hour period after infusion of investigational product because of fluid accumulation or development of ascites.

    Time frame: At 1 year

  29. Phase I rate of VOD/SOS - number of participants affected

    Safety profile of intervention as measured by number of participants affected by VOD/SOS disease in the phase I portion of the study, defined as the occurrence of 2 of the following 3 clinical criteria: * Total serum bilirubin level \>34 μmol/L (\>2.0 mg/dL). * An increase in liver size from baseline or development of right upper quadrant pain of liver origin. * Sudden weight gain \>2.5% during any 72-hour period after infusion of investigational product because of fluid accumulation or development of ascites.

    Time frame: At 1 year

  30. Phase I - Percent of participants with grade 3 + AE/SAEs

    Phase I safety profile of intervention as measured by percent of participants with grade 3 + AE/SAEs

    Time frame: At 1 year

  31. Phase II Non-relapse mortality (NRM)

    Phase II Non-relapse mortality (NRM), defined as time from date of first dose to death due to any cause without prior relapse. Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI

    Time frame: At 3 months after initial treatment

  32. Phase II Relapse

    Phase II relapse rate, defined as time from date of first dose to the date of first relapse. Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI

    Time frame: At 6 months after initial treatment

  33. Phase II Relapse

    Phase II relapse rate, defined as time from date of first dose to the date of first relapse. Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI

    Time frame: At 9 months after initial treatment

  34. Phase II Relapse-related mortality

    Phase II Relapse-related mortality, defined time from date of first dose to death due to any cause with prior relapse Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI

    Time frame: At 1 year after initial treatment

  35. Phase II Relapse-related mortality

    Phase II Relapse-related mortality, defined time from date of first dose to death due to any cause with prior relapse Reported as Cumulative Incidence and 2-sided 80% CI and 2-sided 95% CI

    Time frame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days

  36. Phase II Median OS

    Phase II OS, defined from time from date of first dose to death due to any cause, estimated using Kaplan-Meier, reported as median and 95% CI Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10

    Time frame: At 3 months after initial treatment

  37. Phase II Median OS

    Phase II OS, defined from time from date of first dose to death due to any cause, estimated using Kaplan-Meier, reported as median and 95% CI Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10

    Time frame: At 6 months after initial treatment

  38. Phase II Median OS

    Phase II OS, defined from time from date of first dose to death due to any cause, estimated using Kaplan-Meier, reported as median and 95% CI Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10

    Time frame: At 9 months after initial treatment

  39. Phase II Median OS

    Phase II OS, defined from time from date of first dose to death due to any cause, estimated using Kaplan-Meier, reported as median and 95% CI Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10

    Time frame: At 1 year after initial treatment

  40. Phase II Median OS

    Phase II OS, defined from time from date of first dose to death due to any cause, estimated using Kaplan-Meier, reported as median and 95% CI Difference in time-to-event endpoints will be tested using a 1-sided log-rank test at a significance level of 0.10

    Time frame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days

  41. Phase II Response Rate

    Defined as the proportion of patients with a best overall response of eradicating MRD at the time each patient discontinues treatment with Inotuzumab Ozogamicin

    Time frame: At 3 months after initial treatment

  42. Phase II Response Rate

    Defined as the proportion of patients with a best overall response of eradicating MRD at the time each patient discontinues treatment with Inotuzumab Ozogamicin

    Time frame: At 6 months after initial treatment

  43. Phase II Response Rate

    Defined as the proportion of patients with a best overall response of eradicating MRD at the time each patient discontinues treatment with Inotuzumab Ozogamicin

    Time frame: At 9 months after initial treatment

  44. Phase II Response Rate

    Defined as the proportion of patients with a best overall response of eradicating MRD at the time each patient discontinues treatment with Inotuzumab Ozogamicin

    Time frame: At 1 year after initial treatment

  45. Phase II Response Rate

    Defined as the proportion of patients with a best overall response of eradicating MRD at the time each patient discontinues treatment with Inotuzumab Ozogamicin

    Time frame: Post first dose of inotuzumab ozogamicin on Day 1, Cycle 1, where cycle length is 28 days

  46. Phase II Incidence of myeloid toxicity

    Number of patients who develop myeloid toxicity while on study, defined as grade of anemia, neutropenia and thrombocytopenia CTCAE 4

    Time frame: At 1 year

  47. Phase II Incidence of secondary graft failure

    Number of patients who develop secondary graft failure while on study, defined as: Either cytopenias after initial engraftment (ANC \<500/µL), with (a) donor chimerism of less than 5% or (b) falling donor chimerism with intervention such as second transplant or donor lymphocyte infusion (DLI) or (c) patient death due to cytopenias, and fall in donor chimerism, even if chimerism was \>5%. Exclusion criteria for diagnosis of GF were (a) disease relapse (b) graft versus host disease or (c) other causes of cytopenias such as, viral infections, or drug induced

    Time frame: At 1 year after initial treatment

  48. Phase I incidence of VOD/SOS

    Safety profile of intervention as measured by incidence of VOD/SOS disease in the phase I portion of the study, defined as the occurrence of 2 of the following 3 clinical criteria: * Total serum bilirubin level \>34 μmol/L (\>2.0 mg/dL). * An increase in liver size from baseline or development of right upper quadrant pain of liver origin. * Sudden weight gain \>2.5% during any 72-hour period after infusion of investigational product because of fluid accumulation or development of ascites.

    Time frame: At 1 year

  49. Phase II rate of VOD/SOS - number of participants affected

    Safety profile of intervention as measured by number of participants affected by VOD/SOS disease in the phase I portion of the study, defined as the occurrence of 2 of the following 3 clinical criteria: * Total serum bilirubin level \>34 μmol/L (\>2.0 mg/dL). * An increase in liver size from baseline or development of right upper quadrant pain of liver origin. * Sudden weight gain \>2.5% during any 72-hour period after infusion of investigational product because of fluid accumulation or development of ascites.

    Time frame: At 1 year

  50. Phase II pharmacokinetic (PK) parameters - Cmax

    Phase II PK parameter Cmax is maximum concentration. Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.

    Time frame: At Cycle 1 Day 1 (C1D1) after 0 hours (each cycle is 28 days)

  51. Phase II pharmacokinetic (PK) parameters - Cmax

    Phase II PK parameter Cmax is maximum concentration. Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.

    Time frame: At Cycle 1 Day 1 (C1D1) after 1 hour (each cycle is 28 days)

  52. Phase II pharmacokinetic (PK) parameters - Cmax

    Phase II PK parameter Cmax is maximum concentration. Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.

    Time frame: At Cycle 1 Day 1 (C1D1) after 4 hours (each cycle is 28 days)

  53. Phase II pharmacokinetic (PK) parameters - Cmax

    Phase II PK parameter Cmax is maximum concentration. Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.

    Time frame: At Cycle 1 Day 7 (C1D7) (each cycle is 28 days)

  54. Phase II pharmacokinetic (PK) parameters - Cmax

    Phase II PK parameter Cmax is maximum concentration. Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.

    Time frame: At Cycle 2 Day 1 (C2D1) after 0 hours (each cycle is 28 days)

  55. Phase II pharmacokinetic (PK) parameters - Cmax

    Phase II PK parameter Cmax is maximum concentration. Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.

    Time frame: At Cycle 2 Day 1 (C2D1) after 1 hour (each cycle is 28 days)

  56. Phase II pharmacokinetic (PK) parameters - Cmax

    Phase II PK parameter Cmax is maximum concentration. Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.

    Time frame: At Cycle 4 Day 1 (C4D1) after 0 hours (each cycle is 28 days)

  57. Phase II pharmacokinetic (PK) parameters - Cmax

    Phase II PK parameter Cmax is maximum concentration. Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.

    Time frame: At Cycle 4 Day 1 (C4D1) after 1 hour (each cycle is 28 days)

  58. Phase II pharmacokinetic (PK) parameters - Ctrough

    Phase II PK parameter Ctrough is lowest concertration of Inotuzumab in the blood.Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.

    Time frame: At Cycle 1 Day 1 (C1D1) after 0 hours (each cycle is 28 days)

  59. Phase II pharmacokinetic (PK) parameters - Ctrough

    Phase II PK parameter Ctrough is lowest concertration of Inotuzumab in the blood.Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.

    Time frame: At Cycle1 Day 1 (C1D1) after 1 hour (each cycle is 28 days)

  60. Phase II pharmacokinetic (PK) parameters - Ctrough

    Phase II PK parameter Ctrough is lowest concertration of Inotuzumab in the blood.Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.

    Time frame: At Cycle1 Day 1 (C1D1) after 4 hours (each cycle is 28 days)

  61. Phase II pharmacokinetic (PK) parameters - Ctrough

    Phase II PK parameter Ctrough is lowest concertration of Inotuzumab in the blood.Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.

    Time frame: At Cycle 1 Day 7 (C1D7) (each cycle is 28 days)

  62. Phase II pharmacokinetic (PK) parameters - Ctrough

    Phase II PK parameter Ctrough is lowest concertration of Inotuzumab in the blood.Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.

    Time frame: At Cycle 2 Day 1 (C2D1) after 0 hours (each cycle is 28 days)

  63. Phase II pharmacokinetic (PK) parameters - Ctrough

    Phase II PK parameter Ctrough is lowest concertration of Inotuzumab in the blood.Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.

    Time frame: At Cycle 2 Day 1 (C2D1) after 1 hour (each cycle is 28 days)

  64. Phase II pharmacokinetic (PK) parameters - Ctrough

    Phase II PK parameter Ctrough is lowest concertration of Inotuzumab in the blood.Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.

    Time frame: At Cycle 4 Day 1 (C4D1) after 0 hours (each cycle is 28 days)

  65. Phase II pharmacokinetic (PK) parameters - Ctrough

    Phase II PK parameter Ctrough is lowest concertration of Inotuzumab in the blood.Descriptive statistics (n, mean, SD, %CV, median, minimum, maximum, geometric mean, its associated geometric %CV) of inotuzumab ozogamicin serum concentrations will be presented in tabular form by cycle, day, and nominal time for the PK concentration analysis population.

    Time frame: At Cycle 4 Day 1 (C4D1) after 1 hour (each cycle is 28 days)

07

Study locations

4 of 7 sites recruiting
08

References and documents

Publications

  • Davis KL, Yao CC, Zimmerman JAO, Rau RE. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 Dec;23(12):e257067. doi: 10.6004/jnccn.2025.7067. PubMed 41671463 ↗
  • Metheny LL, Sobecks R, Cho C, Fu P, Margevicius S, Wang J, Ciarrone L, Kopp S, Convents RD, Majhail N, Caimi PF, Otegbeye F, Cooper BW, Gallogly M, Malek E, Tomlinson B, Gerds AT, Hamilton B, Giralt S, Perales MA, de Lima M. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia. Blood Adv. 2024 Mar 26;8(6):1384-1391. doi: 10.1182/bloodadvances.2023011514. PubMed 38170741 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2017 (actual). Primary completion is estimated for Nov 2026, 112 months after the start.

Of 81 non-industry phase 1/2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 119. This study's planned 112 months is above that.

Counting every sponsor, half of 114 studies reached it within 79 months; a quarter within 56 and three quarters within 119.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2017
First posted
Apr 7, 2017
StartActual
Jul 31, 2017
Primary completionEst.
Nov 2026
CompletionEst.
May 2027
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03104491
Lead sponsor
Leland Metheny
Responsible party
Leland Metheny (Principal Investigator, Case Comprehensive Cancer Center) — Sponsor-investigator
First posted
Apr 7, 2017
Start date
Jul 31, 2017
Primary completion
Nov 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Sep 10, 2026

Study contacts

Leland Metheny, MD
Contact
CTUReferral@UHhospitals.org
1-800-641-2422
Ron Sobecks, MD
Contact
sobeckr@ccf.org
216-444-6833
Leland Metheny, MD
principal investigator · University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inotuzumab Ozogamicin

Start the discussion